Skip to main navigation Skip to search Skip to main content

Development of a tractable in vitro model system and high-throughput CRISPR-based tools to study drivers of clonal haematopoiesis

  • Ieva Budriunaite

Student thesis: Doctoral Thesis › Doctor of Philosophy

Abstract

Haematopoeitic stem and progenitor cells (HSPCs) are a small subset of cells responsible for the generation of all mature blood cell lineages. Somatic mutations acquired with age in about 60 genes can cause expansion of mutated HSPCs in bone marrow and subsequently in blood stream in a phenomenon known as clonal haematopoiesis (CH). Mutations in the genes associated with this condition are found in about 10% of the population over the age of 60 and has been linked to increased risk of cardiovascular disease and haematological malignancies, such as acute myeloid leukemia (AML). Several studies have shown that therapeutic agents used in treatment of solid tumours can increase the risk of therapy-related AML (t-AML) in primary cancer survivors. Classed as a distinct type of AML, t-AML has proven harder to treat and has higher risk of mortality. With improved chemotherapy options and subsequent prolonged overall survival in cancer survivors, it has been predicted that the incidence of t-AML will increase.

To understand mechanisms driving expansion of preleukemic HSPCs, we have developed a series of isogenic CRISPR-editing capable murine HSPC-like cell lines. These cells can be stably maintained in vitro and, upon transplantation into irradiated mice, demonstrate robust engraftment and multipotency, much like normal HSPCs. We used these HSPC-like cell lines in unbiased CRISPR-based screens to assess the expansion of preleukemic HSPCs and investigate the impact of various cancer therapies on these cells.

Results of initial large-scale pooled CRISPR-based screens showed expansion of HSPCs with mutations in Dnmt3a, Tet2, Asxl1, Tp53 and others and therefore provide an experimental validation of the mutational patterns seen in population studies. Moreover, tiling strategy employed in the design of the custom sgRNA library has allowed to recapitulate the expansion seen when mutations are observed in a specific region of the gene. This includes the outgrowth of HSPCs with mutations in the RING domain of CBL, mutations in the region upwards of ASXH domain in ASXL1 and others observed in patients with CH. Additional experiments conducted by adding common therapeutic agents showed that our experimental approach successfully replicated treatment resistance observed in HSPCs with specific CH driver mutations. Furthermore, results revealed a three-fold greater expansion of HSPCs with mutation in Asxl1 upon treatment with EPZ-6438, a selective EZH2 inhibitor that is currently used in treatments of follicular lymphoma and epitheliod sarcoma as well as in on-going clinical trials for other cancer types, something that has not been previously observed. Together, these results show that the experimental approach developed during this project could be successfully utilised to assess the effect of established and novel therapies on the expansion phenotype and drug resistance provided by specific mutations driving CH and AML.
Date of Award2026
Original languageEnglish
Awarding Institution
  • University of Dundee
SponsorsWellcome Trust
SupervisorKasper Rasmussen (Supervisor)

Keywords

  • Clonal haemetopoiesis
  • Clonal expansion
  • CRISPR screens
  • ASXL1
  • Pharmacological interventions

Cite this

'